A trial of ‘cognitive remediation therapy’ to improve thinking skills and everyday functioning for people with bipolar disorder

Not Applicable

• Conditions: Bipolar disorder; Mental and Behavioural Disorders

• Registration Number: ISRCTN10362331
• Lead Sponsor: King's College London

Brief Summary

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37968619/ (added 16/11/2023)

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-14
• Last Update Posted: 24 June 2024
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

1. Have a confirmed diagnosis of bipolar disorder type I or II.
2. Be aged between 18 and 65 years.
3. Be euthymic (not in a mood episode) for at least 1 month.
4. Be able to use a computerised device (e.g., computer / smartphone).

Exclusion Criteria

Current participant exclusion criteria as of 04/05/2022:
1. Substance use diagnosis (abuse or dependence).
2. Risk of suicide.
3. Impairing neurological disorder or MCI.
4. Previous cognitive remediation therapy.
5. Unable to communicate fluently in English.
6. Intellectual disability.
7. Currently undergoing psychological therapy or planning imminent treatment change.
8. Non-provision of UK healthcare professional contact.
9. Unable to travel to one of the research sites on a regular basis over 25 weeks.
10. Unable to provide informed consent to participate.

Previous participant exclusion criteria:
1. Substance use diagnosis (abuse or dependence).
2. Risk of suicide.
3. Impairing neurological disorder or MCI.
4. Previous cognitive remediation therapy.
5. Unable to communicate fluently in English.
6. Intellectual disability.
7. Currently undergoing psychological therapy or planning imminent treatment change.
8. Non-provision of UK healthcare professional contact.
9. Unable to provide informed consent to participate.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Everyday functioning, assessed using the Functioning Assessment Short Test. This is measured at baseline, 13 and 25 weeks with the primary outcome timepoint as 25 weeks.